Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

Tilray's mission is to be the most responsible, trusted, and market-leading cannabis and consumer ... Human Health International, and Dr. Marjorie Green, senior vice president and head of oncology, ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and ...